inentertainment.co.uk

Author: GENPREX, INC.

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

April 21, 2026
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

April 20, 2026
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

March 18, 2026
Genprex to Participate at BIO Europe Spring 2026

March 10, 2026
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

February 23, 2026
Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

February 16, 2026
Genprex Provides Clinical Update on Diabetes Gene Therapy Program

January 12, 2026
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

January 9, 2026
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

January 9, 2026
Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

December 1, 2025